$9.37
0.11% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US4884451075
Symbol
ZVRA
Sector
Industry

KemPharm, Inc. Stock price

$9.37
+1.62 20.90% 1M
+0.93 11.02% 6M
+1.03 12.35% YTD
+4.39 88.15% 1Y
+6.28 203.35% 5Y
-254.79 96.45% 10Y
-169.83 94.77% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.01 0.11%
ISIN
US4884451075
Symbol
ZVRA
Sector
Industry

Key metrics

Market capitalization $512.35m
Enterprise Value $509.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.56
P/S ratio (TTM) P/S ratio 12.62
P/B ratio (TTM) P/B ratio 12.49
Revenue growth (TTM) Revenue growth 44.91%
Revenue (TTM) Revenue $40.59m
EBIT (operating result TTM) EBIT $-71.88m
Free Cash Flow (TTM) Free Cash Flow $-67.82m
Cash position $62.63m
EPS (TTM) EPS $-1.70
P/E forward negative
P/S forward 5.51
EV/Sales forward 5.48
Short interest 10.43%
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a KemPharm, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a KemPharm, Inc. forecast:

Buy
100%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
41 41
45% 45%
100%
- Direct Costs 6.32 6.32
171% 171%
16%
34 34
139% 139%
84%
- Selling and Administrative Expenses 64 64
74% 74%
159%
- Research and Development Expense 33 33
23% 23%
81%
-65 -65
20% 20%
-161%
- Depreciation and Amortization 6.48 6.48
160% 160%
16%
EBIT (Operating Income) EBIT -72 -72
26% 26%
-177%
Net Profit -92 -92
81% 81%
-227%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KemPharm, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D.
Neutral
GlobeNewsWire
23 days ago
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D.
Neutral
Seeking Alpha
about one month ago
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Nichol Ochsner - Vice President Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer Adrian Quartel - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Jason Butler -...
More KemPharm, Inc. News

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 67
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today